Our team is attending the Particle Therapy Co-Operative Group conference in Singapore, which will feature our building, The National Cancer Centre of Singapore—a project we are so proud of. The 24-story building has increased clinical care capacity in the region and includes dedicated space for groundbreaking translational research. In addition, the facility includes a four-gantry proton therapy center—the only public institution in Singapore offering the treatment. The NCCS is a destination for truly comprehensive care—from prevention to diagnosis and treatment to survivorship and palliative care. read more about the project here: https://lnkd.in/ePi9fJSk CIAP Architects Pte Ltd #ptcog62 #particletherapy #protontherapy Since they’ll already be overseas, the team is planning a visit to another of our projects – Eastern Advanced Medical Center, Proton Therapy and Comprehensive Oncology Center, in Hong Kong. read more about the project here: https://lnkd.in/e_Pi-3Ky Ronald Lu & Partners
Tsoi Kobus Design’s Post
More Relevant Posts
-
🔖 We're pleased to share that Heidelberg Pharma AG was featured in Biocentury, in an article titled - Cambrian explosion of ADCs at AACR24 - spotlighting the groundbreaking advancements in #ADCs at #AACR2024. 🔖 The article highlights our #ATAC platform, and its exceptional versatility in targeting both proliferating and quiescent tumour cells. 📚 Read the full article here: https://bit.ly/3VUAb8h During AACR, we presented Phase I/IIa data on our lead ATAC compound, HDP-101, designed to target BCMA. Promising results were observed in multiple #myeloma patients, with notable responses and manageable side effects. We look forward to sharing further insights at our R&D webinar on 23 April at 16.00 CEST/15.00 BST, where you can hear directly from the Heidelberg Pharma team, alongside leading Key Opinion Leaders. 🎯 Register to attend the R&D webinar here https://bit.ly/3VYr4U7 #ATAC #ADC #CancerResearch
-
Join us at this upcoming webinar as Mevion and key partners share about seamless integration of the FIT into your oncology department!
The MEVION S250-FIT Proton Therapy System* brings advanced proton therapy technologies with minimal footprint and construction requirements to cancer centers, allowing you to upgrade a LINAC vault to a state-of-the-art proton therapy vault. Join our informative live webinar on February 28th at 2 PM ET in partnership with The National Association for Proton Therapy. Experts from Stanford Health Care, Washington University School of Medicine in St. Louis, H&H Design-Build, and Mevion will discuss: ✅ Site planning, shielding, and construction considerations for the FIT system ✅ Exciting progress updates on the FIT system deployment at Stanford Discover how the FIT system can benefit your radiation oncology practice by signing up for the webinar now: https://hubs.la/Q02kVJ_j0 #Mevion #ProtonTherapy #RadiationOncology #MedTechWebinar #Webinar *The MEVION S250-FIT Proton Therapy System is not yet available for clinical use.
-
📣 The good news isn't stopping as we announce a fabulous new partnership with Gunma University Heavy Ion Medical Center 📣 The renowned Japanese hospital is set to spearhead new research into the reproducibility of upright positioning and new immobilization techniques utilizing Leo Cancer Care's upright patient positioning system. The hospital aims to contribute to this transformative research, validating the future of upright positioning in carbon ion therapy. 💬 Prof. Ohno said, “The development of the upright irradiation system is a Copernican idea having the potential to be an innovative technology that simultaneously reduces the burden of patient positioning and the cost of equipment, and improves irradiation efficiency.” 💬 #uprightradiotherapy #uprightcarboniontherapy #uprightpatientpositioning
Gunma University Heavy Ion Medical Center will install Leo Cancer Care technology to advance research into Upright Patient Positioning for Carbon Ion Therapy — Leo Cancer Care
leocancercare.com
-
We are proud to share that our programme, the Singapore Translational Cancer Consortium, presented a scientific poster on the STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study at these conferences last week: ✅ 10ᵗʰ Asia-Pacific Gastroesophageal Cancer Congress (APGCC) ✅ Singapore Gastric Cancer Consortium’s (SGCC) 15ᵗʰ Annual Scientific Meeting 🌟 ICYMI: Catch the next few poster presentations at these conferences: ➡️ 11th NCIS Annual Research Meeting (NCAM) (12 to 16 August 2024) ➡️ PRECISE - International Health Cohorts Consortium (IHCC) 2024 Conference (21 to 23 August 2024) 🔎 The team at Platform 3 - Translational Research Integration & Support leads the SUPER study. This research is looking to advance biomarker-driven personalised cancer treatment in Singapore, such that more effective therapy with minimal side effects can be developed and ultimately, improve patient outcomes. The study’s objective is to find new ways to predict which patients are suitable for immunotherapy and identify those who may benefit from other treatments instead. To do so, the research team involved in the SUPER study is analysing the data from this study, alongside data from other similar research projects, to adopt the application of cutting-edge technologies to simultaneously detect multiple cancer markers, with the aim to develop novel prediction models to characterise patients with poor prognosis across various clinically-relevant modalities. Congratulations to Dr Michał Marek Hoppe and the team on these speaking engagements! To collaborate with STCC, visit www.stcc.sg #cancerresearch #oncology #immunotherapy #translationalresearch
Multidimensional Data Analysis | Data Visualization | Expert in Biomarker Development + Digital Pathology | Cancer | AI
I am excited to share this infographic summarizing offerings of the #STCC Platform 3 Translational and Pre-clinical Research Pipeline and introducing our #SUPER study use-case. This immense collaborative effort synergizes the #Singapore #cancer ecosystem - a prime example of a cutting-edge, large-scale clinical research study conducted in partnership with multiple public institutions in Singapore 🙂 👏 Eddy Qing Hao Miow, Nimmi Baby, PhD, Yu Hui Cheng, Carmen Yuen, Alexander Lezhava, Jason Yongsheng Chan, MBBS-PhD, Anand Jeyasekharan + Consortium for Clinical Research and Innovation, Singapore (CRIS)
-
📫 Dive into FEAM latest newsletter! 🔎 Highlights: - FEAM Forum Annual Lecture on Precision Medicine in Oncology - The "One Health-One Earth" conference in Cluj-Napoca - News from the Academies and FEAM Forum Partners 📰 You can read the full newsletter here: https://bit.ly/49Siqed Don’t miss out on FEAM latest updates, news from the Academies, and upcoming events and opportunities from our network! Register to our newsletter here: https://bit.ly/44o5hGN #sciencenews #stayinformed #scientificcommunity #newsletter
-
-
Join Vulcan at the Japan Association for Medical Informatics (JAMI) conference, November 22-25, 2023 in Kobe, Japan. Yoshihiro Aoyagi (National Cancer Center Hospital East) will provide an overview of Vulcan and Mika Ogasawara (@Pfizer) will provide insights into Vulcan Adverse Events and Schedule of Activities standards. The Vulcan sessions are scheduled for the 22nd of November. #HL7 #FHIR #HL7Vulcan #interoperability
-
-
Laboratory solutions for clinical trial investigators and pharmaceutical R&D professionals.
Modern research into oncological therapies is on the cutting edge of, not only of life science, but science in general. Complexity and ingenuity that is involved in battling cancer is astounding. Latest knowledge and development in chemistry, biology, diagnostics, and computer science is being actively used to achieve that goal. It is a great pleasure for me to be part of this year's, 10th annual Clinical Operations in Oncology Trials event in Munich. Clinical Trials are a culmination of many years of research for novel oncological therapies, taking them from a concept, an idea to the first patient. Today, together with Oana Radu we are visiting Medicover Integrated Clinical Services Munich Laboratory (a.k.a. IMGM Laboratories GmbH) #clinicaltrials #immunooncology #OncologyEurope #precisionmedicine
-
-
Pencil this session in on your conference agenda this April! #2024NPC.
🔬 Session Spotlight: The Crucial Role of Scientific Research in Advancing Proton Therapy Dive into the world of proton therapy research with experts Ted Hong, MD of Harvard Medical School & Massachusetts General Hospital , Steven Frank, MD of MD Anderson Cancer Center and Jim Metz, MD of Penn Medicine, University of Pennsylvania Health System with moderator Charles Simone, MD of New York Proton Center as they discuss the cutting-edge research shaping the future of PBT and transforming patient outcomes. Register today to secure your spot at #2024NPC: https://bit.ly/48AyPTu 🤝 Engage with peers, thought leaders, and innovators. This incredibly informative session will also be a great opportunity to connect with those at the forefront of proton therapy. We invite all healthcare professionals, researchers, and anyone interested in the progress of cancer treatment to join this compelling session. Be part of the conversation that's driving the future of proton therapy.
-
-
The manuscript below demonstrates an effective strategy for managing prior authorization, minimizing denials, reducing the adminiatrative burden and improving appropriate access to care. #priorauthorization #protontherapy #radiationoncology #oncology #healthcare #patientcare #patientaccess #legionhp
Obtaining prior authorization (PA) before treatment is becoming increasingly burdensome in oncology, especially in radiation oncology. Here, we describe the impact of a strategic novel operational PA redesign to shorten authorization time and to improve patient access to cancer care at a large United States academic proton therapy center. 90% of providers saw a reduction or elimination in prior authorization burden when navigating the insurance process with a different operational strategy. Achieved this while witnessing a parallel increase in appropriate access to care (+30% absolute rise in approvals). Methodology is replicable at other centers, as we show below. If you need expert Prior Auth assistance in radiation oncology, please reach out to our team Legion Healthcare Partners . doi: https://lnkd.in/eA9tquTc #priorauthorization #accesstocare #radiationoncology #protontherapy International Journal of Particle Therapy UF Health Proton Therapy Institute Legion Healthcare Partners
-
#IRgoesClinical For the future of Interventional Radiology it is crucial to become more clinically focussed! IR outpatient clinics and direct access to hospital beds are indispensable tools of the trade. Moreover, inclusion in the hospital´s financial flow - not only as a cost centre - is needed for a bright and flourishing future of IR. The potential is there - it is our job as Interventional Radiologists to move from a vision to clinical reality.
The Clinical Services in IR Task Force was created to advance IR as a clinical specialty. Prof. Dr. Andreas H. Mahnken, Chairperson of the Clinical Services in IR Task Force and member of the Executive Committee, spoke to us to share more about clinical services at his hospital, the direction IR is heading as far as clinical services, his work with the task force, and his hopes for the future. ➡️ https://bit.ly/3RUdDm2 Also, make sure to follow the European Conference on Interventional Oncology for this week's #ECIOtakeover! Prof. Mahnken and resident Caroline Keßler will be sharing their work from Marburg University Hospital in Marburg, Germany. #CIRSEinsider #CIRSEsociety #interventionalradiology #IRads
-
Principal/Owner at Curran Design LLC
1moBeautiful project. Congratulations!